A novel CD47-blocking checkpoint inhibitor has shown promising interim results in a multicenter Phase I trail for relapsed/refractory mycosis fungoides and S̩zary syndrome, the most common types of cutaneous T-cell lymphoma. Christiane Querfeld, MD, PhD, from City of Hope, Duarte, CA, discusses this agent Рthe fusion protein TTI-621 (SIRPaFc), which is injected intralesionally Рhere, and explores potential future avenues of study for this therapy. This interview was recorded at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland.
CD47-blocking checkpoint inhibitor TTI-621 shows promising results for cutaneous T-cell lymphomas
